NIKKEI 225
38,460.08 +907.92 (+2.42%) HANG SENG
17,201.27 +372.34 (+2.21%) CRUDE OIL
82.83 +0.02 (+0.02%) GOLD FUTURES
2,328.70 -9.70 (-0.41%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,575.93 -1,717.11 (-3.22%)
Sanofi (SAN.PA)
| Previous close | 88.85 |
| Open | 89.06 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 87.45 - 89.65 |
| 52-week range | 80.60 - 105.18 |
| Volume | |
| Avg. volume | 1,364,447 |
| Market cap | 109.47B |
| Beta (5Y monthly) | 0.45 |
| PE ratio (TTM) | 20.40 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.76 (4.23%) |
| Ex-dividend date | 13 May 2024 |
| 1y target est | N/A |
- Zacks
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
- Bloomberg
Sanofi Asks Banks to Pitch for $20 Billion OTC Spinoff
(Bloomberg) -- French drugmaker Sanofi has asked banks to pitch for roles on the separation of its consumer-health business, according to people familiar with the matter, one of the biggest deals likely to happen in Europe this year. Most Read from BloombergTaylor Swift Is Proof That How We Critique Music Is BrokenBiden’s Gains Against Trump Vanish on Deep Economic Pessimism, Poll ShowsBiden’s New Chopper Is Demoted After Scorching White House LawnTesla Soars as Musk’s Cheaper EVs Calm Fears Ove
- Zacks
Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.
